KR100351213B1 - 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 - Google Patents

펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR100351213B1
KR100351213B1 KR1019997010523A KR19997010523A KR100351213B1 KR 100351213 B1 KR100351213 B1 KR 100351213B1 KR 1019997010523 A KR1019997010523 A KR 1019997010523A KR 19997010523 A KR19997010523 A KR 19997010523A KR 100351213 B1 KR100351213 B1 KR 100351213B1
Authority
KR
South Korea
Prior art keywords
nle
seq
hpth
cyclo
fmoc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997010523A
Other languages
English (en)
Korean (ko)
Other versions
KR20010012568A (ko
Inventor
콘돈스티븐엠
모리쯔이사벨
Original Assignee
아벤티스 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마슈티칼스 인크. filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20010012568A publication Critical patent/KR20010012568A/ko
Application granted granted Critical
Publication of KR100351213B1 publication Critical patent/KR100351213B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019997010523A 1997-05-14 1998-05-13 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 Expired - Fee Related KR100351213B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4647297P 1997-05-14 1997-05-14
US60/046,472 1997-05-14

Publications (2)

Publication Number Publication Date
KR20010012568A KR20010012568A (ko) 2001-02-15
KR100351213B1 true KR100351213B1 (ko) 2002-09-05

Family

ID=21943653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997010523A Expired - Fee Related KR100351213B1 (ko) 1997-05-14 1998-05-13 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물

Country Status (20)

Country Link
US (2) US6472505B1 (enExample)
EP (1) EP0986395A4 (enExample)
JP (1) JP2001517957A (enExample)
KR (1) KR100351213B1 (enExample)
CN (1) CN1261281A (enExample)
AP (1) AP9901686A0 (enExample)
AU (1) AU746461B2 (enExample)
BG (1) BG103957A (enExample)
BR (1) BR9808786A (enExample)
CA (1) CA2290443A1 (enExample)
EA (1) EA002819B1 (enExample)
HU (1) HUP0003349A3 (enExample)
IL (1) IL132901A0 (enExample)
NO (1) NO995568L (enExample)
OA (1) OA11216A (enExample)
PL (1) PL336803A1 (enExample)
SK (1) SK151599A3 (enExample)
UA (1) UA62967C2 (enExample)
WO (1) WO1998051324A1 (enExample)
ZA (1) ZA984077B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20003798A3 (cs) * 1998-04-15 2001-08-15 Aventis Pharmaceuticals Products, Inc. Způsob výroby cyklických peptidů vázaných k polymernímu nosiči
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU2003233286A1 (en) * 2002-05-16 2003-12-02 Theratechnologies Inc. Pth derivatives resistant to skin proteases
WO2004073587A2 (en) * 2003-02-19 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
CA2529777A1 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
JP5086254B2 (ja) 2005-07-07 2012-11-28 フルクルム エスピー リミテッド Ｓｐ１ポリペプチド、変性ｓｐ１ポリペプチドおよびそれらの使用
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
JP5200027B2 (ja) * 2006-10-13 2013-05-15 イーライ リリー アンド カンパニー Ｐｔｈ受容体モジュレーターとしてのペグ化ｐｔｈおよびその使用
WO2010086867A2 (en) 2009-02-02 2010-08-05 Ramot At Tel Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
CN102448484A (zh) 2009-04-01 2012-05-09 医学研究，基础设施和卫生服务基金的特拉维夫医疗中心 调节角质化细胞增生和分化的方法
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
WO2010137020A1 (en) 2009-05-28 2010-12-02 Yeda Research And Development Co. Ltd. Methods of treating inflammation
RU2557654C3 (ru) 2009-07-29 2017-07-05 Каи Фармасьютикалз, Инк. Терапевтические агенты для снижения уровней паратиреоидного гормона
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2011138785A2 (en) 2010-05-05 2011-11-10 Rappaport Family Institute For Research In The Medical Sciences Use of ccl1 in therapy
BR112012028949B1 (pt) * 2010-05-13 2020-11-17 Chugai Seiyaku Kabushiki Kaisha polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica
EP2600885A2 (en) 2010-08-04 2013-06-12 Ramot at Tel Aviv University, Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
WO2012173694A1 (en) * 2011-06-17 2012-12-20 Fluidic, Inc. Ionic liquid containing sulfonate ions
DK2823040T3 (en) 2012-03-06 2018-11-19 Cellect Biotherapeutics Ltd DEVICES AND METHODS FOR SELECTING APOPTOSE SIGNALING RESISTANT CELLS AND APPLICATIONS THEREOF
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
WO2016128974A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents
WO2016135716A1 (en) 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
CN111375066B (zh) 2015-07-16 2023-04-25 百欧肯治疗有限公司 治疗癌症的组合物及方法
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
EP3464322B1 (en) 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
MX2018016003A (es) 2016-12-01 2019-05-16 Univ Ramot Tratamiento combinado para lesiones neurológicas.
WO2018185768A1 (en) 2017-04-07 2018-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hair care compositions
EP3634991A1 (en) 2017-05-23 2020-04-15 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
WO2019016819A1 (en) 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. NANOPARTICLE COMPOSITIONS
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
EP3717032B1 (en) 2017-11-29 2023-02-15 Ramot at Tel-Aviv University Ltd. Methods of preventing or treating neurogenic shock
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
WO2021005599A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
KR20220151168A (ko) 2020-02-09 2022-11-14 엔엘씨 파르마 엘티디 Sars-cov-2에 대한 신속한 검출 테스트
EP4114473A1 (en) 2020-03-05 2023-01-11 Ariel Scientific Innovations Ltd. Anti-hemorrhaging compositions
WO2021186431A1 (en) 2020-03-16 2021-09-23 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
EP4217370A2 (en) 2020-09-23 2023-08-02 Yeda Research and Development Co. Ltd Methods and compositions for treating coronaviral infections
EP4225903A1 (en) 2020-10-07 2023-08-16 Protalix Ltd. Long-acting dnase
MX2023005235A (es) 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CA3208982A1 (en) 2021-02-18 2022-08-25 Ravid STRAUSSMAN Method of generating vaccines
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
WO2023031934A1 (en) 2021-09-02 2023-03-09 Yeda Research And Development Co. Ltd. Agents that target the glycine arginine-rich domain of nucleolin and uses thereof
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor
WO2024241314A1 (en) 2023-05-22 2024-11-28 Neomanna Ltd Black soldier fly protein extracts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4427827A (en) 1982-10-20 1984-01-24 Usv Pharmaceutical Corporation Synthesis of hormone fragments
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
CA2087087C (en) 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
CA2098639A1 (en) 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE19508672A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
EP0747817B1 (en) 1995-06-07 2003-09-03 Compaq Computer Corporation Method and apparatus for controlling data communication flow in a fault-tolerant multiprocessor system
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
EE9900039A (et) * 1996-08-02 1999-08-16 National Research Council Of Canada Paratüreoidhormooni analoogid osteoporoosi raviks

Also Published As

Publication number Publication date
AU746461B2 (en) 2002-05-02
HUP0003349A2 (hu) 2001-01-29
HUP0003349A3 (en) 2001-12-28
US6472505B1 (en) 2002-10-29
BR9808786A (pt) 2000-07-11
IL132901A0 (en) 2001-03-19
EA199901025A1 (ru) 2000-06-26
EP0986395A4 (en) 2004-12-01
CA2290443A1 (en) 1998-11-19
EP0986395A1 (en) 2000-03-22
US20020132973A1 (en) 2002-09-19
AP9901686A0 (en) 1999-12-31
WO1998051324A1 (en) 1998-11-19
ZA984077B (en) 1998-11-24
CN1261281A (zh) 2000-07-26
JP2001517957A (ja) 2001-10-09
AU7386798A (en) 1998-12-08
SK151599A3 (en) 2000-09-12
PL336803A1 (en) 2000-07-17
KR20010012568A (ko) 2001-02-15
UA62967C2 (en) 2004-01-15
NO995568L (no) 1999-12-29
BG103957A (bg) 2000-04-28
NO995568D0 (no) 1999-11-12
OA11216A (en) 2003-07-10
EA002819B1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
KR100351213B1 (ko) 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물
FI92326C (fi) LHRH:n nonapeptidi- ja dekapeptidianalogeja, jotka ovat käyttökelpoisia LHRH:n antagonisteina
KR0161972B1 (ko) 크기가 감소된 lhrh 동족체
US5110904A (en) Lhrh analogs
KR910002550B1 (ko) Lhrh의 노나펩타이드 및 데카펩타이드 동족체 및 이의 제조방법
AU636301B2 (en) Cyclic grf-analogs ii
US5300492A (en) LHRH analogs
BRPI0717441B1 (pt) Composto, medicamento, e, uso do derivado de metastina
JP2542362B2 (ja) 新規ハロ低級アルキルグアニジノ置換アミノ酸化合物およびその製法
CN101983068B (zh) N末端和c末端取代的人gh-rh拮抗类似物
KR100629013B1 (ko) Ｉｇｆ-ⅰ 및 -ⅱ를 억제하는 ｇｈ-ｒｈ의 길항 유사체
JPH07507330A (ja) ポリペプチドのボンベシン拮抗物質
EP2161037A2 (en) Camptothecin-Somatostatin conjugates
RS52007B (sr) Derivati metastina i njihova upotreba
JP2002502381A (ja) 環状ｃｒｆアンタゴニストペプチド
HU186877B (en) Process for preparing new hormone antagonists releasing luteinizing hormone and acid addition salts thereof
EP0328090A2 (en) LHRH analogs
JPS61210099A (ja) 新規な成長ホルモン放出性ペプチド
JP2012500284A (ja) ペプチド性ｐｔｈ受容体アゴニスト
JPH08505611A (ja) ５位及び６位に修飾アミノアシル残基を有するｌｈｒｈ拮抗薬
NZ251969A (en) Cyclic hexapeptide derivatives and analogs and compositions thereof
MXPA99010562A (en) Peptide parathyroid hormone analogs
MXPA99010560A (en) Detergent compositions
CZ9904022A3 (cs) Peptidové analogy parathyroidálního hormonu
PT94923B (pt) Processo de preparacao de analogos "pseudo" hexapeptidos, heptapeptidos, octapeptidos e nonapeptidos da lhrh e de composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20060816

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20070822

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20070822